Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2025 | $13.00 | Strong Buy | Raymond James |
| 7/11/2025 | $8.00 | Buy | BofA Securities |
| 6/27/2024 | $5.00 | Outperform | BMO Capital Markets |
| 4/9/2024 | $9.00 | Overweight | Piper Sandler |
| 2/1/2023 | $14.00 → $1.50 | Buy → Hold | Jefferies |
| 1/27/2023 | $23.00 → $3.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/9/2022 | $16.00 → $3.00 | Buy → Neutral | Goldman |
| 3/9/2022 | $26.00 | Outperform | Robert W. Baird |
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the secur
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of $200.0 million shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its com
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated with no treatment-related SAEs or DLTs reported as of the June 2026 data cutoff across REVEAL Phase 1/2 and pivotal trials (N=29) 100% of REVEAL Part A patients (N=12, 6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102, with consistent responses across ages and disease severity Longer-term follow‑up showed a durable and deepening treatment effect ≥12 months post-TSHA-102, with functional gains accumulating over time across core disease domains
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
424B5 - Taysha Gene Therapies, Inc. (0001806310) (Filer)
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00
BofA Securities initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $8.00
BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated with no treatment-related SAEs or DLTs reported as of the June 2026 data cutoff across REVEAL Phase 1/2 and pivotal trials (N=29) 100% of REVEAL Part A patients (N=12, 6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102, with consistent responses across ages and disease severity Longer-term follow‑up showed a durable and deepening treatment effect ≥12 months post-TSHA-102, with functional gains accumulating over time across core disease domains
Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE trial ongoing across multiple sites; on track to complete dosing in REVEAL and ASPIRE in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of May 2026 data cutoff; plan to present longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials in Q2 2026 Initiated BLA-enabling P
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on t